ENN 102
Alternative Names: ENN-102Latest Information Update: 06 Oct 2022
At a glance
- Originator EnnovaBio
- Class Antineoplastics
- Mechanism of Action Immune checkpoint protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Research Cancer
Most Recent Events
- 09 Sep 2022 ENN 102 is available for licensing as of 09 Sep 2022. http://www.ennovabio.com/en/xmhz.html
- 09 Sep 2022 Early research in Cancer in China (unspecified route) (EnnovaBio pipeline, September 2022)